The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

MajesTEC-3 gives J&J a way to keep Darzalex relevant beyond its 2029 patent cliff. Credit: aipicte via Shutterstock. At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, ...

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...